[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Karpov
Iu A
IuA
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D017311:Amlodipine / Q000008:administration & dosage / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007211:Indoles; D010919:Placebos; D014665:Vasodilator Agents; D017311:Amlodipine; C052035:trandolapril; D001262:Atenolol; D004656:Enalapril; D014700:Verapamil; D009543:Nifedipine; D020913:Perindopril